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■Etiology and terminology
Chondrosarcoma, the second most common primary
malignancy of bone, is a mesenchymal tumor in which
neoplastic tissue is a fully developed cartilage, and is
nearly 7-22% of all bone tumors. In up to 9-20 % of
chondrosarcoma cases, an additional high-grade mesen-
chymal component is often found. Overall, this variant
represents 1 to 2% of primary bone tumors1-3）. This
high-grade mesenchymal component first fully de-
scribed as “dedifferentiated” chondrosarcoma by
Dahlin and Beabout4）in 1971, is associated with an ag-
gressive clinical course and the survival rate is less
than two years3,5）.
The term “dedifferentiated" implies reversal of a
specialized cell and subsequent redifferentiation into
another specialized cell. The terms “dedifferentiation”
and “malignant transformation” are used synony-
mously to characterize the increasing malignancy
shown by some tumors during their course2). But this
designation is controversial. A common progenitor cell
with the capacity to differentiate has been suggested
to be the cause of this apparent reversal; cartilaginous
and anaplastic components would be derived from a
common progenitor cell6,7). In contrast to the collision
tumor theory, two components each derived from a
separate clone of cells: a component differentiated into
a low-grade chondrosarcoma, and the other component
that fails to differentiate and shows features of high-
grade sarcoma8-10). To avoid this controversial terminol-
ogy, the term “chondrosarcoma with additional mesen-
chymal component” is also used9,11). Many analyses of
dedifferentiated chondrosarcoma are available at the
clinico-pathological level, but cytogenetic or molecular
genetic studies are rare.
The cell biology and oncogenesis of this neoplasm is
still poorly understood, because of its rarity. Recently,
Aigner12) reviewed the biology of dedifferentiated
chondrosarcoma, including three key questions: is de-
differentiated chondrosarcoma of monoclonal origin or
a collision tumor?; if yes, what are the cell biological
mechanisms of this dichotomous differentiation?; and
when does the dichotomy?
■Pathololgy
Dedifferentiated chondrosarcoma is an aggressive
variant of classical chondrosarcoma. Histologically, clas-
sical dedifferentiated chondrosarcoma shows two dif-
ferent tumor components; one resembles morphologi-
cally enchondroma or low-grade conventional chondro-
sarcoma, while the other may comprise a wide variety
of mesenchymal neoplasms, such as malignant fibrous
histiocytoma (MFH), fibrosarcoma, osteosarcoma, and
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rarely rhabdomyosarcoma or angiosarcoma (Figure 1).
Metastatic disease is seen more often than in classic
chondrosarcoma and its prognosis is poor1-4,11）.
■Conventional karyotype analyses
Cytogenetic studies of dedifferentiated chondrosar-
coma are few, because of its rarity. Little is known
about the molecular mechanisms involved in the tu-
morigenesis of dedifferentiated chondrosarcoma. To
date, karyotype analyses of dedifferentiated chondro-
sarcoma have been reportedly recognized in only 8
cases from 6 literatures (Table 1) 6, 13-17). However, these
results were controversial, because the genetic ap-
proaches and the samples in these studies were re-
stricted. From these studies, it appears that dedifferen-
tiated chondrosarcoma is heterogeneous cytogeneti-
cally, as well as histologically. A single or characteristic
anomaly has not yet emerged from these cytogenetic
descriptions.
We analyzed the karyotypes of our cases. Standard
cultures and harvesting procedures were used that
have been described previously18). The karyotypes
were expressed according to the International System
for Human Cytogenetic Nomenclature (ISCN) 199519).
In our current study also, there was no common spe-
cific abnormality in karyotypes (Table 1). The karyo-
types were very complicated by the numerical and
structural changes with markers. In cases which sam-
ples were taken from several locations or at different
times, the clonal karyotypic abnormalities were found
in each case, similar to previous reports6,15). We also
tried and got several specimens, such as biopsy, sur-
gery or metastasis. All our cases showed similar clonal
karyotypic abnormalities in each patient. Of additional
interest was the presence of sharing the similar clonal
karyotypic abnormalities in both the specimens from
chondroid portion and anaplastic portion in our Case 2.
In classical dedifferentiated chondrosarcoma no transi-
tional zone is seen between two tumor components,
which lead to the idea of a primary separate histogene-
sis of two tumor portions9, 20-22). This finding suggests
some sort of collision tumor, derived from two com-
pletely separate tumor cell clones developed from mul-
tipotent mesenchymal stem cells9). However, our kary-
otype data from Case 2 suggests the monoclonal origin
of oncogenesis of dedifferentiated chondrosarcoma, not
collision tumor.
Sawyer23) described the 6q13-21 aberrations in pa-
tients with cartilage tumor. The gene for cartilage-spe-
cific collagen Type IX (COL9A1) has been mapped to6
q12-14, probably 6q1324). The gene type X collagen
(COL10A1) has been mapped to 6q21-2225). In addition,
two oncogenes (FYN and ROS1) have been mapped to
6q21. In view point of these findings, involvement of 6q
13-22 aberrations is showed in three cases (No 5, 7 and
8). In our series, Case 2 (b and c) has shared the abnor-
malities of 6q22 or 6q23. But it is questionable whether
these abnormalities of type X collagen develop the
critical gene as a step of oncogenesis.
■Comparative genomic hybridization (CGH) analyses
CGH is a molecular cytogenetic technique that al-
lows detection of DNA copy number changes26,27).
Information on DNA copy number changes, including
high-level amplification, can be obtained as a global
view of genetic changes. CGH may solve some of the
problems of using standard cytogenetics. However
limitations and difficulties exist when detecting translo-
cations, ploidy changes and analyzing telomeric, and
peri- and hetero-chromatic regions by using CGH27).
DNA was extracted from freshly frozen tissue and
purified by phenol-chloroform. CGH was done almost
as described by Kallioniemi27), and evaluated by using
Quips software (Vysis, Downers Grove, IL) according
to the manufacturer’s instructions.
From our CGH data of dedifferentiated chondrosar-
coma, chromosome 9 was most conspicuous imbalance,
which was suggested critical region (Figure 2). In two
cases there were structural changes, and in another
two cases there were obvious deletion of 9q1.
However, there was no report about oncogene on this
Figure1 Representative pathology
Histologic interpose of a dedifferentiated chondrosarcoma
with rhabdomyosarcomatous elements on the upper left.
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area.
To our knowledge, only one case of dedifferentiated
chondrosarcoma has reportedly demonstrated CGH
analysis7) But their report was without karyotyping
analysis. The cartilagenous component was character-
ized by the deletion of chromosomes 4, 5, 13, 22 and
the distal part of chromosome16p. Chromosome 17
revealed deletion: del (17)(pter-q12) and an amplification
on long arm. In contrast, the anaplastic component
demonstrated amplification on 2p, 8q, 10q, 1q, 12p, 12q,
19p and possibly on1p. Deletion was seen on 2q, 4, 5q,
13, Xp, and Xq. This study illustrated the tremendous
genetic variability of dedifferentiated chondrosarcoma
and a large number of changes per tumor, supporting
the idea that accumulation of genetic changes is impor-
tant for the tumor progression, just as occurs in the
conventional chondrosarcoma. Larramendy28,29) stated
that the gain of 20q (especially q12-qter), 8q24.1-qter,
20p and 14q24-qter is observed mainly. Moreover, re-
current and metastatic tumors showed a gain of chro-
mosome 7 and 5q14-q32. In 45 cases of conventional
chondrosarcoma of his reports28,29), there was no abnor-
mality of 9q. The imbalance of 9q might be critical re-
gion to change up to the dedifferentiated chondrosar-
coma.
■Conclusion
This review aimed to characterize the cytogenetics
findings of dedifferentiated chondrosarcoma. But, cyto-
genetic anomaly has not emerged from previous de-
scription. Our cytogenetic data suggests the monoclo-
nal origin of oncogenesis of dedifferentiated chondro-
sarcoma, not collision tumor.
Moreover, we provide the genomic imbalance of 9q
might be critical region to dedifferentiate. The rele-
vance of the newly identified regions of gains and
losses found in this study remains to be determined by
future studies, focusing on the identification of critical
genes in these regions.
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